GlaxoSmithKline
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 244
- Registration Number
- NCT04446351
- Locations
- 🇰🇷
GSK Investigational Site, Seoul, Korea, Republic of
Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 117
- Registration Number
- NCT04428333
- Locations
- 🇬🇧
GSK Investigational Site, Sutton, United Kingdom
Safety, Immunogenicity and Efficacy of GSK S. Aureus Candidate Vaccine (GSK3878858A) When Administered to Healthy Adults (Dose-escalation) and to Adults 18 to 64 Years of Age With a Recent S. Aureus Skin and Soft Tissue Infection (SSTI)
- Conditions
- Interventions
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 632
- Registration Number
- NCT04420221
- Locations
- 🇬🇧
GSK Investigational Site, West Midlands, United Kingdom
A Study of Belantamab Mafodotin Monotherapy in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2024-05-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT04398745
- Locations
- 🇸🇬
GSK Investigational Site, Singapore, Singapore
A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function
- First Posted Date
- 2020-05-21
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT04398680
- Locations
- 🇰🇷
GSK Investigational Site, Suwon-si, Gyeonggi-do, Korea, Republic of
Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease
- Conditions
- Interventions
- First Posted Date
- 2020-05-06
- Last Posted Date
- 2022-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1156
- Registration Number
- NCT04376684
- Locations
- 🇬🇧
GSK Investigational Site, Liverpool, United Kingdom
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Melrilimab (GSK3772847) in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2020-04-28
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 65
- Registration Number
- NCT04366349
- Locations
- 🇺🇸
GSK Investigational Site, Anaheim, California, United States
A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2024-04-18
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT04349280
- Locations
- 🇪🇸
GSK Investigational Site, Sevilla, Spain
Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)
- Conditions
- Interventions
- First Posted Date
- 2020-04-03
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2916
- Registration Number
- NCT04333147
- Locations
- 🇬🇧
GSK Investigational Site, Coventry, United Kingdom
Bioequivalence (BE) Study of Test Griseofulvin 500 Milligram (mg) Tablets Versus Reference and Dose Proportionality Study of Test Griseofulvin 250 mg and 500 mg Tablets Under Fed Conditions
- Conditions
- Interventions
- First Posted Date
- 2020-03-24
- Last Posted Date
- 2020-12-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 36
- Registration Number
- NCT04318535
- Locations
- 🇮🇳
GSK Investigational Site, Navi Mumbai, India